GlaxoSmithKline lung drug Anoro approved in Europe

GlaxoSmithKline said on Thursday its new inhaled lung drug, Anoro, had been approved in Europe as a treatment for chronic lung disease, boosting its respiratory franchise.

A final green light had been expected for the product, which was developed with Theravance, following a recommendation from European experts in February.